Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
An update from OncoSil Medical Ltd ( (AU:OSL) ) is now available.
OncoSil Medical Limited has announced an investor webinar to discuss recent advancements in the commercialisation strategy for its OncoSil™ device, a treatment for pancreatic cancer. The updates include German Federal Joint Committee approval for a new treatment method, authorization for 120 German hospitals to negotiate funding under the innovation funding program, and the lifting of post-market restrictions following EU Medical Device Regulation certification. These developments are expected to significantly impact OncoSil’s market reach and operational capabilities, enhancing its positioning in the medical device industry.
More about OncoSil Medical Ltd
OncoSil Medical Limited is a company specializing in the development of cancer treatment devices, particularly the OncoSil™ brachytherapy device, which is designed for treating locally advanced unresectable pancreatic cancer. The device offers a targeted treatment approach by delivering Phosphorous-32 directly into pancreatic tumors, in combination with chemotherapy. OncoSil has received breakthrough device designation in several regions including the EU, UK, and US, and is approved for sale in over 30 countries.
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$32.25M
For a thorough assessment of OSL stock, go to TipRanks’ Stock Analysis page.
